Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Rdhl save search
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
Published: 2023-02-16 (Crawled : 17:00) - biospace.com/
RDHL | $0.35 -13.41% 910K
|
Health Technology
|
| O: -1.87%
H: 9.52%
C: 8.1%
rhb-102 bekinda meeting application positive
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
Published: 2023-02-16 (Crawled : 17:00) - biospace.com/
RDHL | $0.35 -13.41% 910K
|
Health Technology
|
| O: -1.87%
H: 9.52%
C: 8.1%
rhb-102 biopharma meeting positive
RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome
Published: 2023-02-15 (Crawled : 18:00) - biospace.com/
RDHL | $0.35 -13.41% 910K
|
Health Technology
|
| O: 1.72%
H: 3.29%
C: 0.47%
fda biopharma meeting opaganib nuclear positive
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
RDHL | $0.35 -13.41% 910K
|
Health Technology
|
| O: 15.68%
H: 26.31%
C: 9.06%
rhb-107 covid-19 positive results publication study phase 2
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
Published: 2022-11-17 (Crawled : 14:20) - biospace.com/
RDHL | $0.35 -13.41% 910K
|
Health Technology
|
| O: 13.43%
H: 0.0%
C: -10.89%
biopharma opaganib nuclear positive
RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
Published: 2022-11-14 (Crawled : 12:20) - prnewswire.com
RDHL | $0.35 -13.41% 910K
|
Health Technology
|
| O: 11.03%
H: 0.89%
C: -7.56%
nuclear program positive
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
Published: 2022-06-23 (Crawled : 12:00) - biospace.com/
RDHL | $0.35 -13.41% 910K
|
Health Technology
|
| O: 33.06%
H: 0.0%
C: -24.67%
biopharma positive
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
Published: 2022-03-01 (Crawled : 14:30) - biospace.com/
RDHL | $0.35 -13.41% 910K
|
Health Technology
|
| O: 0.46%
H: 0.45%
C: -10.45%
rhb-107 covid-19 phase 2 covid positive
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
Published: 2021-06-21 (Crawled : 12:00) - biospace.com/
RDHL | $0.35 -13.41% 910K
|
Health Technology
|
| O: 0.43%
H: 1.57%
C: -1.14%
covid presentation phase 2 biopharma positive opaganib covid-19
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
Published: 2020-12-31 (Crawled : 15:07) - prnewswire.com
RDHL | $0.35 -13.41% 910K
|
Health Technology
|
| O: 0.93%
H: 7.87%
C: -6.48%
covid positive biopharma topline phase 2 opaganib
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
WISA 4 | $5.33 204.57% 190M
|
Electronic Technology
TPET | $0.5189 124.54% 38M
|
n/a
SXTC | $1.78 52.14% 33M
|
Health Technology
JAGX | $0.1771 49.07% 540M
|
Health Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
FNCH | $2.98 32.74% 400K
|
Professional, Scientific, and T...
PALI | $5.51 32.45% 28M
|
Manufacturing
VERO | $0.804 31.8% 110K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.